- Home
- IMRX vs ADAG Comparison
IMRX vs ADAG Comparison
Compare IMRX & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMRX
- ADAG
- Stock Information
- Founded
- IMRX 2008
- ADAG 2011
- Country
- IMRX United States
- ADAG China
- Employees
- IMRX N/A
- ADAG N/A
- Industry
- IMRX Biotechnology: Pharmaceutical Preparations
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- IMRX Health Care
- ADAG Health Care
- Exchange
- IMRX Nasdaq
- ADAG Nasdaq
- Market Cap
- IMRX 68.4M
- ADAG 76.3M
- IPO Year
- IMRX 2021
- ADAG 2021
- Fundamental
- Price
- IMRX $3.38
- ADAG $1.82
- Analyst Decision
- IMRX Strong Buy
- ADAG Strong Buy
- Analyst Count
- IMRX 4
- ADAG 1
- Target Price
- IMRX $13.25
- ADAG $8.00
- AVG Volume (30 Days)
- IMRX 2.9M
- ADAG 68.3K
- Earning Date
- IMRX 08-05-2025
- ADAG 07-24-2025
- Dividend Yield
- IMRX N/A
- ADAG N/A
- EPS Growth
- IMRX N/A
- ADAG N/A
- EPS
- IMRX N/A
- ADAG N/A
- Revenue
- IMRX N/A
- ADAG $103,204.00
- Revenue This Year
- IMRX N/A
- ADAG $6,488.89
- Revenue Next Year
- IMRX N/A
- ADAG $57.50
- P/E Ratio
- IMRX N/A
- ADAG N/A
- Revenue Growth
- IMRX N/A
- ADAG N/A
- 52 Week Low
- IMRX $1.00
- ADAG $1.33
- 52 Week High
- IMRX $3.87
- ADAG $3.58
- Technical
- Relative Strength Index (RSI)
- IMRX 69.21
- ADAG 60.58
- Support Level
- IMRX $2.29
- ADAG $1.73
- Resistance Level
- IMRX $3.87
- ADAG $1.98
- Average True Range (ATR)
- IMRX 0.44
- ADAG 0.07
- MACD
- IMRX 0.10
- ADAG -0.01
- Stochastic Oscillator
- IMRX 77.72
- ADAG 70.45
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.